<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04455399</url>
  </required_header>
  <id_info>
    <org_study_id>20200102</org_study_id>
    <nct_id>NCT04455399</nct_id>
  </id_info>
  <brief_title>Time Efficiency Comparison of Two IntraVitreal Injection Techniques</brief_title>
  <acronym>TIVI</acronym>
  <official_title>Time Efficiency Comparison of Two Intravitreal Injection Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Eye and Laser Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Eye and Laser Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency
      and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique
      using a dual blade speculum among patients undergoing IVI for various indications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single-center, randomized, clinical trial (RCT) comparing the efficiency and
      safety of a single-use IIG with a traditional technique using a dual blade speculum among
      patients undergoing IVI for various indications.

      The investigators will include eyes of adult patients scheduled to undergo unilateral or
      bilateral IVI for neovascular age-related macular degeneration (nAMD), polypoidal choroidal
      vasculopathy (PCV), diabetic macular edema (DME), retinal vein occlusion (RVO), choroidal
      neovascular membrane from pathologic myopia (PM) and uveitis. The investigators will exclude
      eyes with a history of extraocular or intraocular infection within 3 months of the scheduled
      IVI date, scleral thinning, history of previous glaucoma surgery, history of pars plana
      vitrectomy, hypersensitity to the IVI drug, propracaine or povidone iodine, and inability to
      understand the informed consent form.

      The eyes will be randomly assigned in 1:1 fashion into two injection arms: intravitreal
      injection guide (IIG) and dual blade speculum (DBS). At the time of injection, a random
      number generator will be used to generate an odd or even number for each eye. Odd eyes will
      be assigned to IIG and even eyes will be assigned to DBS. For same day bilateral injection,
      once the first eye is randomized to one technique, the second eye will be automatically
      assigned to the other technique. The study will be conducted in compliance with the
      Declaration of Helsinki. All patients will provide informed consent prior to start of study
      procedures.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intravitreal Injection Guide (Malosa, Beaver Visitec International, Waltham, MA)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of intravitreal injection procedure</measure>
    <time_frame>At time of injection procedure</time_frame>
    <description>Duration in seconds from application to removal of single-blade or dual blade speculum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>Immediately and up to 1 month after the intravitreal injection procedure</time_frame>
    <description>Frequency of adverse events and serious adverse events after intravitreal injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retinal Vein Occlusion With Macular Edema</condition>
  <condition>Uveitic Macular Edema</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Intravitreal injection guide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single use, combination ocular surface caliper to determine point of intravitreal injection and set-depth injection guide to limit injection needle entry into the eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual blade eyelid speculum</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dual blade eyelid speculum to open eyelids followed by Castroviejo surgical caliper to measure injection point 3.5 mm from limbus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravitreal injection guide (Malosa)</intervention_name>
    <description>A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion</description>
    <arm_group_label>Intravitreal injection guide</arm_group_label>
    <other_name>Malosa intravitreal injection guide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual Blade Eyelid Speculum</intervention_name>
    <description>A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.</description>
    <arm_group_label>Dual blade eyelid speculum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        * Eyes of adult patients requiring intravitreally injected medications for non-infectious
        indications

        Exclusion Criteria:

          -  History of extraocular or intraocular infection within 3 months of the scheduled IVI
             date

          -  Scleral thinning

          -  History of previous glaucoma surgery

          -  History of pars plana vitrectomy

          -  Hypersensitivity to the IVI drug, proparacaine or povidone iodine

          -  Inability to understand the informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harvey S Uy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peregrine Eye and Laser Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harvey Uy</last_name>
    <phone>+639175239332</phone>
    <email>harveyuy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rheamel Navarro</last_name>
    <phone>+63288900115</phone>
    <email>rhea.navarro@peregrineeye.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peregrine Eye and Laser Instittute</name>
      <address>
        <city>Makati City</city>
        <state>MM</state>
        <zip>1209</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peregrine Eye and Laser Institute</investigator_affiliation>
    <investigator_full_name>Harvey Siy Uy</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>intravitreal injection</keyword>
  <keyword>intravitreal injecton guide</keyword>
  <keyword>macular edema</keyword>
  <keyword>time efficiency</keyword>
  <keyword>anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

